Survival from prostate cancer was so high -- 99 percent, regardless of which approach men had -- that the results call into question not only what treatment is best but also whether any treatment at all is needed for early-stage cases. And that in turn adds to concern aboutscreening...
PROBLEM TO BE SOLVED: To provide prostate cancer therapeutic agents for the treatment of metastatic stage prostate cancer or for the delay or prevention of progression of localized or locally advanced prostate cancer into metastatic stage, the agents being gonadotropic hormone releasing hormone receptor ...
Androgen deprivation therapy (ADT) is an effective hormonal therapy for treating early stages of prostate cancer. The lowering or preventing androgen hormones (testosterone and dihydrotestosterone) from entering into the prostate cells have shown to shrink or slow the growth of the malignant cells. Sev...
Results. The mean first-year cost of treating localized prostate cancer in CaPSURE was $6375. When broken down by stage, the mean first-year cost for patients with Stage T1c was $5731, with T2a/b was $6426, and with Stage T2c was $6810 (P = 0.059). The initial treatment choice was...
Prostate cancer (PC) is a leading cause of death in older men. Androgen deprivation therapy (ADT) is considered the standard-of-care for men with locally advanced disease. However, continuous androgen ablation is associated with acute and long-term adver
Oncology found that the average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a ...
Nanoparticles have many potential benefits for diagnosing and treating metastatic cancer, including the ability to transport complex molecular cargoes to the major sites of metastasis, such as the lungs, liver and lymph nodes, as well as targeting to specific cell populations within these organs. ...
P. et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol. 34, 646–653 (2003). Article PubMed Google Scholar Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer ...
7. A method of monitoring a change in stage of prostate cancer in a patient comprising: (a) identifying a patient having prostate cancer; (b) periodically determining levels of CSG in cells, tissues, or bodily fluid from said patient; and (c) comparing the periodically determined CSG levels...
4.The method of claim 1, wherein the determining comprises comparing the DNA sequence of the tumor-infiltrating leukocytes with the DNA sequence of non-cancerous cells. 5.The method of claim 1, wherein the determining further comprises generating a report that indicates the presence of one or...